fingolimod hydrochloride has been researched along with 2019 Novel Coronavirus Disease in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 63 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Battaglia, MA; Brichetto, G; Caleri, F; Callari, G; Carmisciano, L; Clerico, M; Cordera, S; Cordioli, C; Da Rin, G; Di Sapio, A; Ferrò, MT; Franciotta, D; Frau, J; Gandoglia, I; Gazzola, P; Inglese, M; Iodice, R; Landi, D; Lapucci, C; Laroni, A; Liberatore, G; Mannironi, A; Marinelli, F; Pasquali, L; Perego, G; Repice, AM; Salvetti, M; Schiavetti, I; Serrati, C; Signoriello, E; Sormani, MP; Stromillo, ML; Tassinari, T; Uccelli, A; Ulivelli, M | 1 |
| Amato, MP; Banwell, B; Chitnis, T; Deiva, K; Hemingway, C; Krupp, L; Pohl, D; Rostasy, K; Sandesjö, F; Wassmer, E; Waubant, E; Wickström, R | 1 |
| Aaberge, IAS; Aarseth, J; Andersen, JT; Berge, T; Celius, EG; Harbo, HF; Holmøy, T; König, M; Lorentzen, ÅR; Lund-Johansen, F; Munthe, LA; Mygland, Å; Myhr, KM; Nygaard, GO; Schikora-Rustad, S; Søraas, A; Torgauten, HM; Torkildsen, Ø; Tran, TT; Vaage, EB; Vaage, JT; Wergeland, S | 1 |
| Berger, J; Campbell Cree, BA; DeLasHeras, V; Greenberg, BM; Hach, T; Hemmer, B; Kilaru, A; Kundu, U; Sullivan, R; Ward, BJ | 1 |
| Bianco, A; Capone, F; Cicia, A; Cortese, A; Cruciani, A; De Arcangelis, V; De Giglio, L; Di Lazzaro, V; Ferraro, E; Lucchini, M; Mirabella, M; Motolese, F; Rossi, M; Sancetta, B | 1 |
| Audoin, B; Bensa, C; Bourre, B; De Seze, J; Januel, E; Louapre, C; Maarouf, A; Maillart, E; Moisset, X; Pelletier, J; Pique, J; Vermersch, P; Vukusic, S | 1 |
| Akbayır, E; Baliç, N; Erol, R; Kızılay, T; Türkoğlu, R; Tüzün, E; Yılmaz, V | 1 |
| Amato, MP; Battaglia, MA; Brambilla, L; Brescia Morra, V; Capobianco, M; Cavalla, P; Comi, G; De Luca, G; Ferraro, D; Filippi, M; Granella, F; Iaffaldano, P; Lepore, V; Lucisano, G; Lugaresi, A; Lus, G; Malucchi, S; Maniscalco, GT; Manni, A; Moiola, L; Montepietra, S; Mosconi, P; Paolicelli, D; Patti, F; Pesci, I; Petracca, M; Ponzio, M; Ragonese, P; Sola, P; Tedeschi, G; Toscano, S; Totaro, R; Trojano, M; Vianello, M | 1 |
| Achiron, A; Dolev, M; Dreyer-Alster, S; Falb, R; Flechter, S; Gurevich, M; Harari, G; Magalashvili, D; Mandel, M; Menascu, S; Sonis, P | 1 |
| Altieri, M; Bisecco, A; Capuano, R; Chianese, A; Conte, M; Coppola, N; Donnarumma, G; Franci, G; Galdiero, M; Gallo, A; Grimaldi, E; Tedeschi, G | 1 |
| Bar-Haim, E; Hellmann, MA; Karni, A; Karussis, D; Miller, A; Milo, R; Staun-Ram, E | 1 |
| Bakshi, R; Gillani, RL; Klawiter, EC; Manzano, GS; Mateen, FJ; Matiello, M; Rice, DR; Tauhid, SS | 1 |
| Balboni, A; Borghi, A; Camilli, F; Di Felice, G; Giannoccaro, MP; Lazzarotto, T; Leone, M; Liguori, R; Lodi, V; Lugaresi, A; Panzera, I; Rinaldi, R; Salvi, F; Tappatà, M; Vacchiano, V; Zenesini, C | 1 |
| Boekel, L; Brinke, AT; Duurland, M; Eftimov, F; Hagen, RR; Killestein, J; Konijn, VAL; Kuijpers, TW; Kummer, LYL; Palomares Cabeza, V; Rispens, T; Stalman, EW; Steenhuis, M; Tas, SW; van Dam, KPJ; van de Sandt, CE; van Ham, SM; van Kempen, ZLE; Verstegen, NJM; Wieske, L; Wolbink, G | 1 |
| Annovazzi, P; Bonavita, S; Caleri, F; Cavalla, P; Clerico, M; Cocco, E; Cola, G; Conte, A; Cordioli, C; Di Filippo, M; Di Sapio, A; Docimo, R; Ferraro, D; Immovilli, P; Iodice, R; Lanzillo, R; Laroni, A; Liberatore, G; Pasquali, L; Patti, F; Rilla, MT; Ruscica, F; Salvetti, M; Schiavetti, I; Signoriello, E; Sormani, MP; Stromillo, ML; Teresa Ferrò, M; Ulivelli, M | 1 |
| Bellmann-Strobl, J; Böttcher, C; Braginets, A; Braun, J; de la Rosa, K; Dingeldey, M; Fauchere, F; Giesecke-Thiel, C; Henze, L; Holenya, P; Jürchott, K; Klein, F; Kruse, B; Loyal, L; Mangold, M; Maraj, A; Meyer-Arndt, L; Nitsche, A; Paul, F; Ratswohl, C; Reimer, U; Sander, LE; Sawitzki, B; Thiel, A; Vanshylla, K | 1 |
| Altieri, M; Bisecco, A; Capuano, R; Conte, M; Coppola, N; d'Ambrosio, A; Donnarumma, G; Galdiero, M; Gallo, A; Grimaldi, E; Medici, N; Tedeschi, G | 1 |
| Baba, C; Cevik, S; Dogan, Y; Kaya, E; Ozakbas, S; Ozcelik, S; Ozdogar, AT; Samedzada, U | 1 |
| Carmagnini, D; Carta, E; Castiglia, P; Chessa, P; Cocco, E; Cucca, F; Delogu, G; Devoto, M; Farina, G; Fiorillo, E; Floris, M; Frau, J; Fronza, M; Idda, ML; Lobina, M; Lodde, V; Loizedda, A; Lorefice, L; Marini, MG; Masala, M; Mingoia, M; Pilotto, S; Pitzalis, M; Solla, P; Steri, M; Uzzau, S; Virdis, F; Zarbo, RI; Zoledziewska, M | 1 |
| Aykaç, S; Eliaçık, S | 1 |
| Bigaud, M; Brinkmann, V; Dahlke, F; de Micco, M; Graham, G; Hach, T; Nicoletti, F; Petricoul, O; Piani-Meier, D; Shakeri-Nejad, K; Turrini, R | 1 |
| Baker, D; Forte, E; Giovannoni, G; James, LK; Kang, AS; Pryce, G; Schmierer, K | 1 |
| Ciccone, A; Debouverie, M; Mathey, G; Prunis, C | 1 |
| Abhari, AP; Eighani, N; Etemadifar, M; Nouri, H; Salari, M; Sedaghat, N | 1 |
| Agrati, C; Aiello, A; Altera, AMG; Bettini, A; Bevilacqua, N; Coppola, A; Cuzzi, G; Farroni, C; Galgani, S; Garbuglia, AR; Gasperini, C; Goletti, D; Haggiag, S; Lapa, D; Meschi, S; Nicastri, E; Petrone, L; Prosperini, L; Puro, V; Quartuccio, ME; Ruggieri, S; Salmi, A; Tortorella, C; Vanini, V | 1 |
| Ansarin, K; Ardalan, M; Hejazian, SM; Hejazian, SS; Pourbayram Kaleybar, S; Teymouri, S; Zununi Vahed, S | 1 |
| Barcellini, L; Capello, E; Cellerino, M; Franciotta, D; Inglese, M; Lapucci, C; Laroni, A; Schiavetti, I; Sormani, MP; Tazza, F; Uccelli, A | 1 |
| Chitsaz, A; Etemadifar, M; Ghasemi Movaghar, A; Lotfi, N; Salari, M; Sayahi, F; Sedaghat, N | 1 |
| Bakkioui, S; Brieva, L; Gil Sánchez, A; González-Mingot, C; Peralta, S; Quibus, L; Ruiz-Fernández, E; San Pedro-Murillo, E; Sancho-Saldaña, A; Solana, MJ; Torres, P | 1 |
| Battaglia, MA; Brichetto, G; Caleri, F; Clerico, M; Conte, A; Cordera, S; Ferrò, MT; Franciotta, D; Frau, J; Gandoglia, I; Gazzola, P; Grimaldi, L; Inglese, M; Marinelli, F; Pasquali, L; Rilla, MT; Salvetti, M; Schiavetti, I; Signoriello, E; Sormani, MP; Stromillo, ML; Uccelli, A; Ulivelli, M | 1 |
| Celius, EG; Chopra, A; Harbo, HF; Holmøy, T; Høgestøl, EA; Jørgensen, KK; Kjønstad, IF; König, M; Lund-Johansen, F; Mjaaland, S; Munthe, LA; Nygaard, GO; Ravussin, A; Solum, G; Syversen, SW; Vaage, JT; Wolf, AS; Øverås, MH | 1 |
| Altieri, M; Bisecco, A; Boffa, L; Capuano, R; Cavalla, P; Cocco, E; Cordioli, C; De Luca, G; Di Gregorio, M; Fantozzi, R; Gajofatto, A; Gallo, A; Gasperini, C; Guaschino, C; Lorefice, L; Nociti, V; Paolicelli, D; Pinardi, F; Prosperini, L; Radaelli, M; Ragonese, P; Solaro, C; Torri Clerici, V; Tortorella, C | 1 |
| Akçin, R; Arslan, G; Baba, C; Beckmann, Y; Bilge, U; Boz, C; Bünül, SD; Demir, S; Dinç, Ö; Doğan, İG; Efendi, H; Elverdi, T; Gezen, O; Gümüş, H; Gündüz, T; Karabudak, R; Koç, R; Kocazeybek, B; Köseoğlu, M; Kürtüncü, M; Özakbaş, S; Özen, PA; Saip, S; Şen, S; Siva, A; Terzi, M; Tezer, DÇ; Tuncer, A; Turan, ÖF; Tütüncü, M; Uygunoğlu, U; Uzunköprü, C | 1 |
| Al-Naqshbandi, M; El Ayoubi, NK; Ghanim, Z; Habahbeh, M; Hatem, A; Joudi, H; Raki, A; Sahraian, MA | 1 |
| Belin, L; Charbonnier-Beaupel, F; Hippolyte, A; Ibrahim, M; Januel, E; Jeantin, L; Louapre, C; Malet, I; Marcelin, AG; Marot, S; Pourcher, V; Rosenzwajg, M; Soulié, C; Zafilaza, K | 1 |
| Gombolay, GY; Kaufmann, C; Morris, M | 1 |
| Axelsson, M; Brandt, AF; Carlin, G; Gafvelin, G; Grönlund, H; Hessa, T; Högelin, KA; Khademi, M; Kockum, I; Lycke, J; Malmeström, C; Olsson, T; Piehl, F; Rabenstein, M; Thomas, OG | 1 |
| Robertson, NP; Willis, MD | 1 |
| Bussone, G; Louapre, C; Lubetzki, C; Maillart, E; Papeix, C; Pourcher, V; Roux, T | 1 |
| Barzegar, M; Khorvash, F; Maghzi, AH; Mirmosayyeb, O; Nehzat, N; Sarrafi, R; Shaygannejad, V | 1 |
| Adam, EH; Bauer, B; Foerch, C; Friedauer, L; Wolf, T | 1 |
| Valencia-Sanchez, C; Wingerchuk, DM | 1 |
| Bowen, JD; Brink, J; Brown, TR; Lucassen, EB; Repovic, P; Smoot, K; Wundes, A | 1 |
| Azimi, AR; Nourbakhsh, B; Safavi, F | 1 |
| Diaz, V; Guevara, C; Naves, R; Rosas, CS; Villa, E | 1 |
| Amor, S; Baker, D; Giovannoni, G; Kang, AS; Schmierer, K | 1 |
| Badolato, R; Capra, R; Chiarini, M; Giacomelli, M; Imberti, L; Moratto, D; Paghera, S; Rossi, N | 1 |
| Filippi, M; Preziosa, P; Rocca, MA | 1 |
| Gomez-Mayordomo, V; González-García, N; Matías-Guiu, J; Matías-Guiu, JA; Montero-Escribano, P; Porta-Etessam, J | 1 |
| Angarano, G; Bavaro, DF; Bollo, L; Guerra, T; Iaffaldano, P; Monno, L; Paolicelli, D; Saracino, A; Trojano, M | 1 |
| Bergamaschi, R; Fabbro, BD; Mallucci, G; Zito, A | 1 |
| Ghobrial, RM; Kloc, M | 1 |
| Ahmed, SF; Alroughani, R; Ibrahim Ismail, I; Salama, S | 1 |
| Tasat, DR; Yakisich, JS | 1 |
| Battaglia, MA; Capobianco, M; Carmisciano, L; Comi, G; Cordioli, C; De Rossi, N; Immovilli, P; Moiola, L; Patti, F; Radaelli, M; Salvetti, M; Schiavetti, I; Sormani, MP; Tedeschi, G; Trojano, M; Zaratin, P | 1 |
| Baldanti, F; Bergamaschi, R; Fabbro, BD; Franciotta, D; Gastaldi, M; Mallucci, G; Zito, A | 1 |
| Capone, F; Di Lazzaro, V; Ferraro, E; Motolese, F | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
| Amato, MP; Derfuss, T; Fonderico, M; Hemmer, B; Portaccio, E; Selmaj, K; Stankoff, B; Tintorè, M | 1 |
| Filippi, M; Gelibter, S; Moiola, L; Nozzolillo, A; Orrico, M; Preziosa, P; Sangalli, F | 1 |
| Abulaban, A; Aggad, H; Al Bunyan, R; Al Jumah, M; Al Malik, Y; AlKhawajah, M; Almejally, M; Alnajashi, H; Alshamrani, F; Bohlega, S; Cupler, EJ; ElBoghdady, A; Makkawi, S; Qureshi, S; Shami, S | 1 |
| Acar, P; Baba, C; Carmisciano, L; Demir, S; Efendi, H; Gumus, H; Gunduz, T; Gungor Dogan, I; Kale Icen, N; Karabudak, R; Koseoglu, M; Ozakbas, S; Petek Balci, B; Schiavetti, I; Sen, S; Siva, A; Sormani, MP; Terzi, M; Tuncer, A; Turan, OF; Tutuncu, M; Uygunoglu, U; Uzunkopru, C; Yetkin, MF | 1 |
| A, N; C, Z; L, M; M, F; S, G; S, L | 1 |
5 review(s) available for fingolimod hydrochloride and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
Topics: COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2023 |
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Vaccination | 2023 |
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Betacoronavirus; CD8-Positive T-Lymphocytes; Cladribine; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Deprescriptions; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immune Evasion; Immunity, Innate; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Lymphopenia; Macrophages; Monocytes; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Toluidines | 2020 |
Rationale for the use of sphingosine analogues in COVID-19 patients.
Topics: COVID-19; COVID-19 Drug Treatment; Cytokines; Fingolimod Hydrochloride; Humans; SARS-CoV-2; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators | 2021 |
Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia.
Topics: Consensus; COVID-19; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pandemics; RNA, Viral; SARS-CoV-2; Saudi Arabia | 2021 |
2 trial(s) available for fingolimod hydrochloride and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
Topics: Antibodies, Viral; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity; Immunoglobulin G; Lymphocyte Count; Multiple Sclerosis; Prospective Studies; SARS-CoV-2 | 2022 |
The effect of Fingolimod on patients with moderate to severe COVID-19.
Topics: COVID-19; Fingolimod Hydrochloride; Humans; SARS-CoV-2; Sphingosine | 2023 |
56 other study(ies) available for fingolimod hydrochloride and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Topics: 2019-nCoV Vaccine mRNA-1273; Adult; Antibodies, Monoclonal, Humanized; Antibody Formation; BNT162 Vaccine; Cladribine; COVID-19; COVID-19 Vaccines; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Male; Middle Aged; Multiple Sclerosis; Prospective Studies; Rituximab; Treatment Outcome | 2021 |
Current international trends in the treatment of multiple sclerosis in children-Impact of the COVID-19 pandemic.
Topics: Adult; Child; COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; SARS-CoV-2 | 2021 |
Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
Topics: Antibodies, Viral; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Humoral; Immunization, Secondary; Immunoglobulin G; Multiple Sclerosis; Pandemics; Rituximab; RNA, Messenger; SARS-CoV-2; Vaccination | 2023 |
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series.
Topics: Adolescent; Adult; Aged; Azetidines; Benzyl Compounds; Child; Clinical Trials as Topic; Comorbidity; COVID-19; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Product Surveillance, Postmarketing; Retrospective Studies; Severity of Illness Index; Young Adult | 2021 |
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Humoral; Immunogenicity, Vaccine; Immunoglobulin G; Multiple Sclerosis; SARS-CoV-2 | 2022 |
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
Topics: BNT162 Vaccine; COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Neuromyelitis Optica; SARS-CoV-2 | 2022 |
Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis.
Topics: Antibodies, Viral; Antibody Formation; COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccination; Vaccines, Inactivated | 2022 |
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Topics: Adult; Age Factors; Case-Control Studies; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time Factors | 2022 |
Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Viral; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunoglobulin G; mRNA Vaccines; Multiple Sclerosis; RNA, Messenger; SARS-CoV-2; Vaccination; Vaccines, Synthetic | 2022 |
Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Topics: BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Cellular; Immunoglobulin G; Israel; mRNA Vaccines; Multiple Sclerosis; RNA, Messenger; SARS-CoV-2; Vaccination; Vaccines, Synthetic | 2022 |
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
Topics: Antibodies, Viral; COVID-19; Fingolimod Hydrochloride; Humans; Middle Aged; Multiple Sclerosis; SARS-CoV-2 | 2022 |
Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
Topics: 2019-nCoV Vaccine mRNA-1273; Adult; Aged; Antibodies, Viral; Autoimmune Diseases of the Nervous System; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Humoral; Immunoglobulin G; Longitudinal Studies; Middle Aged; SARS-CoV-2 | 2022 |
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod.
Topics: Antibodies, Monoclonal, Humanized; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Cellular; Immunization, Secondary; Interferon-gamma; Multiple Sclerosis; Prospective Studies; SARS-CoV-2; T-Lymphocytes; Vaccination | 2022 |
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Retrospective Studies; SARS-CoV-2 | 2022 |
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
Topics: Antibodies, Viral; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Cellular; mRNA Vaccines; Multiple Sclerosis; Prospective Studies; RNA, Messenger; SARS-CoV-2; Vaccination; Vaccines, Synthetic | 2022 |
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
Topics: Antibodies, Viral; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunoglobulin G; mRNA Vaccines; Multiple Sclerosis; RNA, Messenger; SARS-CoV-2 | 2022 |
Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies.
Topics: Antibodies, Viral; COVID-19; COVID-19 Vaccines; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; RNA, Messenger; Vaccines, Inactivated | 2022 |
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study.
Topics: BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Cross-Sectional Studies; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Multiple Sclerosis; SARS-CoV-2; Vaccination | 2022 |
What are the trends in the treatment of multiple sclerosis in recent studies? - A bibliometric analysis with global productivity during 1980-2021.
Topics: Alemtuzumab; COVID-19; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Recurrence | 2022 |
Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Vaccination; Vaccines | 2023 |
Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.
Topics: Cohort Studies; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2; Vaccination; Vaccines | 2023 |
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.
Topics: Antibodies, Viral; COVID-19; COVID-19 Vaccines; Cytokines; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Multiple Sclerosis; RNA, Messenger; T-Lymphocytes | 2023 |
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis.
Topics: Adaptor Proteins, Signal Transducing; Adult; Antibodies, Viral; B-Lymphocytes; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Prospective Studies; SARS-CoV-2; Vaccination | 2023 |
Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity.
Topics: Antibodies, Viral; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Multiple Sclerosis; Pilot Projects; Vaccines, Inactivated | 2023 |
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Topics: Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Cellular; Multiple Sclerosis; Natalizumab; Prospective Studies; SARS-CoV-2; Vaccination | 2023 |
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
Topics: Antibodies, Viral; Antibody Formation; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Prospective Studies; Rituximab; SARS-CoV-2; Vaccination | 2023 |
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; Rituximab; SARS-CoV-2; Vaccination | 2023 |
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; mRNA Vaccines; Multiple Sclerosis; Natalizumab; RNA, Messenger; SARS-CoV-2 | 2023 |
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Topics: Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Cross-Sectional Studies; Female; Fingolimod Hydrochloride; Humans; Male; Multiple Sclerosis; Prospective Studies; RNA, Messenger; SARS-CoV-2; Vaccination | 2023 |
Current and future trends in multiple sclerosis management: Near East perspective.
Topics: COVID-19; Cross-Sectional Studies; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Lebanon; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization.
Topics: Antibodies, Neutralizing; Antibodies, Viral; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Multiple Sclerosis; Prospective Studies; RNA, Messenger; SARS-CoV-2; Seroconversion; Vaccination | 2023 |
Antibody response to SARS-CoV-2 vaccination or infection in a prospective cohort of children with neuroinflammatory diseases.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Viral; Antibody Formation; Child; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Neuroinflammatory Diseases; Prospective Studies; SARS-CoV-2; Vaccination | 2023 |
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Topics: Adaptive Immunity; Alemtuzumab; Antibodies; Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Interferon-gamma; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Vaccination | 2023 |
Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2.
Topics: Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Natalizumab; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus | 2020 |
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Deprescriptions; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Noninvasive Ventilation; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed | 2020 |
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; C-Reactive Protein; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Deprescriptions; Female; Ferritins; Fibrin Fibrinogen Degradation Products; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Interleukin-6; L-Lactate Dehydrogenase; Lymphopenia; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Pneumonia, Viral; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index | 2020 |
COVID-19 in MS: Initial observations from the Pacific Northwest.
Topics: Adult; Aged; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunocompromised Host; Immunosuppressive Agents; Interferons; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Northwestern United States; Nursing Homes; Oregon; Pandemics; Pneumonia, Viral; Severity of Illness Index; Toluidines; Travel; Washington | 2020 |
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Topics: Adult; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Disease Susceptibility; Dyspnea; Epidemics; Female; Fever; Fingolimod Hydrochloride; Glatiramer Acetate; Hospitalization; Humans; Hydroxybutyrates; Immunocompromised Host; Immunologic Factors; Intensive Care Units; Interferons; Iran; Lung; Lymphocyte Depletion; Male; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Severity of Illness Index; Toluidines; Tomography, X-Ray Computed | 2020 |
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chile; Coronavirus Infections; COVID-19; Decision Making; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Guideline Adherence; Guidelines as Topic; Health Behavior; Humans; Immunologic Factors; Interferons; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pandemics; Pneumonia, Viral; Quarantine; SARS-CoV-2; World Health Organization; Young Adult | 2020 |
Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
COVID-19 will change MS care forever - No.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Disease Management; Drug Substitution; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Telemedicine; Viral Vaccines | 2020 |
Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.
Topics: COVID-19; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; RNA, Viral; SARS-CoV-2 | 2021 |
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
Topics: Adult; COVID-19; Crotonates; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Nitriles; SARS-CoV-2; Seroconversion; Toluidines | 2020 |
Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod.
Topics: Adult; Asymptomatic Diseases; Betacoronavirus; Coronavirus Infections; COVID-19; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Topics: Azetidines; Benzyl Compounds; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; rhoA GTP-Binding Protein; SARS-CoV-2 | 2020 |
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Child; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunologic Factors; Interferon-beta; Kuwait; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Recurrence; Rituximab; SARS-CoV-2; Surveys and Questionnaires; Telephone; Toluidines; Young Adult | 2020 |
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Immunologic Factors; Immunosuppressive Agents; Intensive Care Units; Interferons; Male; Middle Aged; Mortality; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Severity of Illness Index; Young Adult | 2021 |
Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
Topics: Adult; Antibodies, Viral; Asymptomatic Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Multiple Sclerosis; Natalizumab; RNA, Viral; SARS-CoV-2; Seroepidemiologic Studies | 2021 |
COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
Topics: COVID-19; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2 | 2021 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
Topics: COVID-19; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2 | 2022 |
Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?
Topics: Atrioventricular Block; COVID-19; Fingolimod Hydrochloride; Humans; Lysophospholipids; Pandemics; SARS-CoV-2; Sphingosine | 2021 |
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
Topics: Adult; Cohort Studies; COVID-19; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2 | 2021 |
Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Humoral; Italy; Multiple Sclerosis; Retrospective Studies; Vaccination | 2022 |